Streetbeat News

ICCM

IceCure Medical Ltd

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

1.38

Mkt cap

80M

Volume

166K

High

1.44

P/E Ratio

-5.07

52-wk high

1.66

Low

1.38

Div yield

N/A

52-wk low

0.48

IceCure Medical Ltd. (NASDAQ:ICCM) has appointed Shad Good as Vice President of Sales for North America. Good will be responsible for building a sales infrastructure in anticipation of a broader commercialization of the company's ProSense System in the U.S. and Canada. The company is awaiting the FDA's response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:06 pm

In the last quarter, Icecure Medical (NASDAQ:ICCM) received five bullish analyst ratings with an average price target of $3.2, implying an upside from the current price of $0.9862. This average has decreased by 24.71% from the previous average price target of $4.25.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 6:00 pm

Alliance Global Partners analyst Ben Haynor maintains a 'Buy' rating on Icecure Medical (NASDAQ:ICCM) but lowers the price target from $4.25 to $4.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:17 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Icecure Medical (NASDAQ:ICCM) and maintained a price target of $3.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:46 am

Icecure Medical has submitted a regulatory filing to the FDA for its early-stage low risk breast cancer treatment for patients at high risk for surgery. The company is awaiting the FDA's response and is also working on increasing market awareness and reimbursement for ProSense procedures.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:13 pm

Icecure Medical (NASDAQ:ICCM) reported a 30% decrease in quarterly losses, from $(0.24) per share last year to $(0.17) per share this year. The company also reported a 8.93% increase in sales, from $1.51 million last year to $1.65 million this year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:11 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Icecure Medical (NASDAQ:ICCM) and maintained a price target of $3.

Portfolio Pulse from richadhand@benzinga.com

July 25, 2023 | 10:19 am

IceCure Medical Ltd. (NASDAQ:ICCM) has received approval from Health Canada for its ProSense System, a minimally-invasive cryoablation technology that destroys tumors by freezing. The approval strengthens the company's market potential in North America. IceCure's CEO, Eyal Shamir, stated that the approval will create synergies in the broader North American market and the company plans to expand its activities into Canada.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 12:10 pm

IceCure Medical has expanded the distribution of its ProSense system into Portugal through an agreement with Medicinália Cormédica. The ProSense system is used for the treatment of benign and malignant tumors.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:03 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 2:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.